“o. itemList. length” “this. config. text. ariaShown”
“This. config. text. ariaFermé”
Johnson
The first phase of phase 2 of the J vaccine is expected to
Participants will get the first dose between September 14 and 22, either one injection of the vaccine or two injections one month apart. The dose will be tested as opposed to an organization that will get placebo treatment. After receiving the first dose, participants have joined -visits every week the first month. During the current month, some other dose of vaccine may adhere to evaluations every seven days. The objective of the test is to determine the protection of the vaccine and to evaluate the number of doses and the maximum appropriate time of treatment in terms of protection and efficacy.
In addition to Spain, the Phase 2 trial is also carried out in the Netherlands, Belgium and Germany. Trials in all 3 countries are expected to last two months and have a total of 550 participants.
J,
JNJ shares have fully recovered since falling to a six-year low in March and are now trading 1. 3% higher than at the beginning of the year (see JNJ’s action research on TipRanks).
Credit Suisse analyst Matt Miksic recently reiterated a buy note to share with a value target of $ 163, saying that JNJ’s intra-quarterly investigation of the U. S. pharmaceutical business for July appears to more or less follow his estimates of the third trimester.
“JNJ Pharma franchises are less affected by COVID-19 than device companies, which are more directly similar to elective procedures, which makes inventory exciting for investors involved about the possible resurgence of COVID-19 infections and the corresponding perspective has an effect on trends in elective surgery,” Miksic wrote in a note to investors.
In general, the rest of the street stock has Miksic’s bullish perspective on the action. Strong Buy analysts have 7 unanimous buying odds. This is with an average value target of $166. 86, indicating a prospective increase of 13% over the next 12 months.
Related News: PFizer CEO: Our Covid-19 vaccine could be ready in the US. But it’s not the first time Until the end of the year Approved Medtronic’s first diabetes control system for young children Gilead Inks ImMU Agreement of $21 billion, adding Trodelvy to its arsenal of oncology
Citigroup, Wayfair’s spouse on new cards
Scientific Games up 15% after Caledonia, takes 34. 9% stake
Cowen is optimistic about Domino’s Pizza and increases PT
Molecular completes the drug Covid-19 and plans a human trial in November